Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

215 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized single and multiple ascending dose study in healthy volunteers of LTI-291, a centrally penetrant glucocerebrosidase activator.
den Heijer JM, Kruithof AC, van Amerongen G, de Kam ML, Thijssen E, Grievink HW, Moerland M, Walker M, Been K, Skerlj R, Justman C, Dudgeon L, Lansbury P, Cullen VC, Hilt DC, Groeneveld GJ. den Heijer JM, et al. Among authors: moerland m. Br J Clin Pharmacol. 2021 Sep;87(9):3561-3573. doi: 10.1111/bcp.14772. Epub 2021 Mar 2. Br J Clin Pharmacol. 2021. PMID: 33576113 Free PMC article.
Recombinant human serum amyloid P in healthy volunteers and patients with pulmonary fibrosis.
Dillingh MR, van den Blink B, Moerland M, van Dongen MG, Levi M, Kleinjan A, Wijsenbeek MS, Lupher ML Jr, Harper DM, Getsy JA, Hoogsteden HC, Burggraaf J. Dillingh MR, et al. Among authors: moerland m. Pulm Pharmacol Ther. 2013 Dec;26(6):672-6. doi: 10.1016/j.pupt.2013.01.008. Epub 2013 Feb 4. Pulm Pharmacol Ther. 2013. PMID: 23380438 Clinical Trial.
Lack of a clinically relevant effect of sugammadex on anti-Xa activity or activated partial thromboplastin time following pretreatment with either unfractionated or low-molecular-weight heparin in healthy subjects.
De Kam PJ, Kruithof AC, van Lierop MJ, Moerland M, Dennie J, Troyer MD, Langdon RB, Gutstein DE, Burggraaf J, El Galta R. De Kam PJ, et al. Among authors: moerland m. Int J Clin Pharmacol Ther. 2014 Aug;52(8):631-41. doi: 10.5414/CP202091. Int J Clin Pharmacol Ther. 2014. PMID: 24800921 Clinical Trial.
The use of biomarkers in human pharmacology (Phase I) studies.
Cohen AF, Burggraaf J, van Gerven JM, Moerland M, Groeneveld GJ. Cohen AF, et al. Among authors: moerland m. Annu Rev Pharmacol Toxicol. 2015;55:55-74. doi: 10.1146/annurev-pharmtox-011613-135918. Epub 2014 Oct 6. Annu Rev Pharmacol Toxicol. 2015. PMID: 25292425 Review.
Antisense-mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial.
van Poelgeest EP, Hodges MR, Moerland M, Tessier Y, Levin AA, Persson R, Lindholm MW, Dumong Erichsen K, Ørum H, Cohen AF, Burggraaf J. van Poelgeest EP, et al. Among authors: moerland m. Br J Clin Pharmacol. 2015 Dec;80(6):1350-61. doi: 10.1111/bcp.12738. Epub 2015 Oct 24. Br J Clin Pharmacol. 2015. PMID: 26261033 Free PMC article. Clinical Trial.
Injection site reactions after subcutaneous oligonucleotide therapy.
van Meer L, Moerland M, Gallagher J, van Doorn MB, Prens EP, Cohen AF, Rissmann R, Burggraaf J. van Meer L, et al. Among authors: moerland m. Br J Clin Pharmacol. 2016 Aug;82(2):340-51. doi: 10.1111/bcp.12961. Epub 2016 May 31. Br J Clin Pharmacol. 2016. PMID: 27061947 Free PMC article. Review.
215 results